Najoua Lalaoui

RIPK3 controls MAIT cell accumulation during development but not during infection

Timothy Patton, Zhe Zhao, Xin Yi Lim, Eleanor Eddy, Huimeng Wang, Adam G Nelson, Bronte Ennis, Sidonia BG Eckle, Michael NT Souter, Troi J Pediongco, Hui-Fern Koay, Jian-Guo Zhang, Tirta M Djajawi, Cynthia Louis, Najoua Lalaoui, Nicolas Jacquelot, Andrew M Lew, Daniel G Pellicci, James McCluskey, Yifan Zhan, et al.

Journal article  |  2023  |  CELL DEATH & DISEASE

Cell death mechanisms in T lymphocytes vary according to their developmental stage, cell subset and activation status. The cell de..

Ubiquitylation of RIPK3 beyond-the-RHIM can limit RIPK3 activity and cell death

Daniel Frank, Sarah E Garnish, Jarrod J Sandow, Ashley Weir, Lin Liu, Elise Clayer, Lizeth Meza, Maryam Rashidi, Simon A Cobbold, Simon R Scutts, Marcel Doerflinger, Holly Anderton, Kate E Lawlor, Najoua Lalaoui, Andrew J Kueh, Vik Ven Eng, Rebecca L Ambrose, Marco J Herold, Andre L Samson, Rebecca Feltham, et al.

Journal article  |  2022  |  ISCIENCE

Pathogen recognition and TNF receptors signal via receptor interacting serine/threonine kinase-3 (RIPK3) to cause cell death, incl..

Tankyrase-mediated ADP-ribosylation is a regulator of TNF-induced death

Lin Liu, Jarrod J Sandow, Deena M Leslie Pedrioli, Andre L Samson, Natasha Silke, Tobias Kratina, Rebecca L Ambrose, Marcel Doerflinger, Zhaoqing Hu, Emma Morrish, Diep Chau, Andrew J Kueh, Cheree Fitzibbon, Marc Pellegrini, Jaclyn S Pearson, Michael O Hottiger, Andrew Webb, Najoua Lalaoui, John Silke

Journal article  |  2022  |  SCIENCE ADVANCES

Tumor necrosis factor (TNF) is a key component of the innate immune response. Upon binding to its receptor, TNFR1, it promotes pro..

25 years of research put RIPK1 in the clinic

Lin Liu, Najoua Lalaoui

Journal article  |  2021  |  SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Receptor Interacting Protein Kinase 1 (RIPK1) is a key regulator of inflammation. To warrant cell survival and appropriate immune ..

The necroptotic cell death pathway operates in megakaryocytes, but not in platelet synthesis

Diane Moujalled, Pradnya Gangatirkar, Maria Kauppi, Jason Corbin, Marion Lebois, James M Murphy, Najoua Lalaoui, Joanne M Hildebrand, John Silke, Warren S Alexander, Emma C Josefsson

Journal article  |  2021  |  CELL DEATH & DISEASE

Necroptosis is a pro-inflammatory cell death program executed by the terminal effector, mixed lineage kinase domain-like (MLKL). P..

MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis

Andre L Samson, Ying Zhang, Niall D Geoghegan, Xavier J Gavin, Katherine A Davies, Michael J Mlodzianoski, Lachlan W Whitehead, Daniel Frank, Sarah E Garnish, Cheree Fitzgibbon, Anne Hempel, Samuel N Young, Annette V Jacobsen, Wayne Cawthorne, Emma J Petrie, Maree C Faux, Kristy Shield-Artin, Najoua Lalaoui, Joanne M Hildebrand, John Silke, et al.

Journal article  |  2020  |  NATURE COMMUNICATIONS

Mixed lineage kinase domain-like (MLKL) is the terminal protein in the pro-inflammatory necroptotic cell death program. RIPK3-medi..

Targeting triple-negative breast cancers with the Smac-mimetic birinapant

Najoua Lalaoui, Delphine Merino, Goknur Giner, Francois Vaillant, Diep Chau, Lin Liu, Tobias Kratina, Bhupinder Pal, James R Whittle, Nima Etemadi, Jean Berthelet, Julius Grasel, Cathrine Hall, Matthew E Ritchie, Matthias Ernst, Gordon K Smyth, David L Vaux, Jane E Visvader, Geoffrey J Lindeman, John Silke

Journal article  |  2020  |  Cell Death and Differentiation

Smac mimetics target inhibitor of apoptosis (IAP) proteins, thereby suppressing their function to facilitate tumor cell death. Her..

MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells

Athena F Phoa, Ariadna Recasens, Fadi MS Gurgis, Tara A Betts, Sharleen V Menezes, Diep Chau, Kristiina Nordfors, Joonas Haapasalo, Hannu Haapasalo, Terrance G Johns, Brett W Stringer, Bryan W Day, Michael E Buckland, Najoua Lalaoui, Lenka Munoz

Journal article  |  2020  |  CANCERS

MAPK-activated protein kinase 2 (MK2) has diverse roles in cancer. In response to chemotherapy, MK2 inhibition is synthetically le..

Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease

Najoua Lalaoui, Steven E Boyden, Hirotsugu Oda, Geryl M Wood, Deborah L Stone, Diep Chau, Lin Liu, Monique Stoffels, Tobias Kratina, Kate E Lawlor, Kristien JM Zaal, Patrycja M Hoffmann, Nima Etemadi, Kristy Shield-Artin, Christine Biben, Wanxia Li Tsai, Mary D Blake, Hye Sun Kuehn, Dan Yang, Holly Anderton, et al.

Journal article  |  2020  |  NATURE

RIPK1 is a key regulator of innate immune signalling pathways. To ensure an optimal inflammatory response, RIPK1 is regulated post..

Antagonism of IAPs enhances CAR T cell efficacy

J Michie, PA Beavis, AJ Freeman, SJ Vervoort, KM Ramsbottom, V Narasimhan, EJ Lelliott, N Lalaoui, RG Ramsay, RW Johnstone, J Silke, PK Darcy, I Voskoboinik, CJ Kearney, J Oliaro

Conference Proceedings  |  2019  |  EUROPEAN JOURNAL OF IMMUNOLOGY